Revenue: As of FY2025, the actual value is USD 17.44 M.EPS: As of FY2025, the actual value is USD -2.07.EBIT: As of FY2025, the actual value is USD -19.89 M.<h4>Revenue</h4>Total revenue for Vivos Therapeutics, Inc. increased by $2,412 thousand, or 16%, to $17,443 thousand in 2025 from $15,031 thousand in 2024. This growth was primarily driven by increases of approximately $4.8 million in sleep testing services and $2.0 million from Vivos treatment to patients at two SCN locations in 2025 . Product revenue decreased by $1,387 thousand to $6,487 thousand in 2025 from $7,874 thousand in 2024, attributed to a decrease in appliance sales to Vivos Integrated Providers (VIPs) and increased discounts of $1.6 million in 2025 compared to $0.2 million in 2024 . Service revenue, however, rose by $3,799 thousand to $10,956 thousand in 2025 from $7,157 thousand in 2024 . VIP enrollment revenue significantly decreased by approximately 80% to $0.5 million in 2025 from $2.5 million in 2024, reflecting a strategic shift in the business model . Sales of oral appliance arches and tooth positioners totaled 25,441 units in 2025, compared to 16,182 units in 2024, with tooth positioner sales increasing by approximately $1.0 million .<h4>Gross Profit</h4>Cost of sales increased by $889 thousand, or 15%, to $6,901 thousand in 2025 from $6,012 thousand in 2024, mainly due to higher costs in diagnostic services and additional staff for new sleep center affiliations . Gross profit increased by $1,523 thousand, or 17%, to $10,542 thousand in 2025, up from $9,019 thousand in 2024, while the gross profit margin remained constant at 60% for both years .<h4>Operating Expenses</h4>General and administrative expenses rose by $9,849 thousand to $27,727 thousand in 2025, compared to $17,878 thousand in 2024, largely due to $6.7 million in costs associated with SCN’s operations and related Vivos treatment centers . Sales and marketing expenses decreased by - $331 thousand to $1,400 thousand in 2025 from $1,731 thousand in 2024, mainly due to reduced commissions and convention expenses . Depreciation and amortization expense increased by $728 thousand to $1,309 thousand in 2025, compared to $581 thousand in 2024, reflecting an increase in depreciable assets from new sleep center acquisitions and affiliations .<h4>Operating Loss and Net Loss</h4>Operating loss increased to - $19,894 thousand in 2025 from - $11,171 thousand in 2024 . The net loss for 2025 was - $21,230 thousand, an increase of - $10,094 thousand compared to - $11,136 thousand in 2024 . The net loss attributable to stockholders was - $21,170 thousand in 2025, compared to - $11,136 thousand in 2024 .<h4>Cash Flow</h4>Net cash used in operating activities increased to - $15,263 thousand in 2025 from - $12,691 thousand in 2024 . Net cash used in investing activities significantly increased to - $7,526 thousand in 2025 from - $568 thousand in 2024, primarily due to capital expenditures of approximately $5.2 million for the SCN Acquisition and $2.3 million for internal-use software development . Net cash provided by financing activities was $18,558 thousand in 2025, compared to $17,876 thousand in 2024, driven by proceeds from common stock issuance, debt, and warrants .<h4>Financial Position</h4>As of December 31, 2025, cash and cash equivalents were $2,029 thousand . The company reported an accumulated deficit of approximately - $125.4 million and total liabilities of approximately $26.7 million . Total stockholders’ equity/(deficit) was - $1,490 thousand as of December 31, 2025 .<h4>Outlook and Guidance</h4>Vivos Therapeutics, Inc. aims to increase diagnostic and treatment revenue in upcoming quarters, projecting that each Sleep Optimization (SO) team could generate over $500,000 per month with contribution margins exceeding 50% . The company expects to scale its SCN locations, addressing constraints like physical space and provider recruitment . Vivos Therapeutics, Inc. anticipates that its new medical provider-focused strategic marketing and distribution alliance model will positively impact revenue growth and stockholders’ equity in future fiscal quarters .

Vivos Therapeutics | 10-K: FY2025 Revenue: USD 17.44 M